Janux Therapeutics
JANX
176 hedge funds and large institutions have $860M invested in Janux Therapeutics in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 69 increasing their positions, 41 reducing their positions, and 38 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 41
16% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 38
1% more funds holding
Funds holding: 174 → 176 (+2)
5.02% less ownership
Funds ownership: 108.44% → 103.42% (-5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
46% less capital invested
Capital invested by funds: $1.59B → $860M (-$733M)
54% less call options, than puts
Call options by funds: $6.05M | Put options by funds: $13.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$46.2M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$42.1M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$35.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$130M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$71.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$55.9M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$22.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.6M |
JANX Hedge Fund Activity: Q4 2025 in Review
176 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2025, worth a combined $860M — down 46% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new JANX positions and 38 closed out — a net gain of 6 holders — while 69 added to existing stakes and 41 trimmed.
The largest buyer was State Street, adding an estimated $46.2M. The largest seller was Fidelity Investments, cutting an estimated $130M.
- 176 institutional investors held Janux Therapeutics (JANX) as of Q4 2025, up from 174 in Q3 2025.
- Funds reported $860M of Janux Therapeutics stock for Q4 2025, down 46% quarter-over-quarter.
- 44 funds opened new Janux Therapeutics positions in Q4 2025 and 38 closed out, a net change of +6 holders.
- The largest Janux Therapeutics buyer in Q4 2025 was State Street, an estimated $46.2M added.
- The largest Janux Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $130M sold.
Based on aggregated 13F filings for Q4 2025.